Sanofi is transferring a portfolio of 20 mature medicines to Cheplapharm.
The agreement includes three manufacturing sites located in Hungary, Singapore, and France.
Sanofi will receive a 26.4% equity stake in Cheplapharm in exchange for these assets.
This transaction deepens a strategic collaboration between the two companies that began in 2014.
The move aligns with Sanofi's long-term strategy to streamline operations and focus on innovative medicines.